Phase I Safety Study of Intratumoural Injection of Clostridium Novyi-NT Spores in Patients With Treatment-refractory Solid Tumour Malignancies
Active, no longer recruiting
Phase of Trial: Phase I
Latest Information Update: 28 Jun 2017
At a glance
- Drugs Clostridium novyi-NT (Primary)
- Indications Solid tumours
- Focus Adverse reactions
- Sponsors BioMed Valley Discoveries
- 21 Jun 2017 Planned primary completion date changed from 1 Jun 2017 to 1 Jan 2018.
- 21 Jun 2017 Status changed from recruiting to active, no longer recruiting.
- 08 Feb 2017 Planned number of patients changed from 30 to 24.
Most Recent Events
Table of Contents
- At a glance
- Trial Overview
- Trial Details
- Trial Centres
- Trial History